346 results about "Surfactant free" patented technology

The present invention provides a method of producing pristine or non-oxidized nano graphene platelets (NGPs) that are highly conductive. The method comprises: (a) providing a pristine graphitic material comprising at least a graphite crystallite having at least a graphene plane and an edge surface; (b) dispersing multiple particles of the pristine graphitic material in a liquid medium containing therein no surfactant to produce a suspension, wherein the multiple particles in the liquid have a concentration greater than 0.1 mg / mL and the liquid medium is characterized by having a surface tension that enables wetting of the liquid on a graphene plane exhibiting a contact angle less than 90 degrees; and (c) exposing the suspension to direct ultrasonication at a sufficient energy or intensity level for a sufficient length of time to produce the NGPs. Pristine NGPs can be used as a conductive additive in transparent electrodes for solar cells or flat panel displays (e.g., to replace expensive indium-tin oxide), battery and supercapacitor electrodes, and nanocomposites for electromagnetic wave interference (EMI) shielding, static charge dissipation, and fuel cell bipolar plate applications.

The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and / or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.

The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and / or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.

The present invention is directed to compositions, products and methods useful for bone and tooth mineralization. The compositions comprise polymer microcapsules containing aqueous salt solutions. The shells of the microcapsules can be semi-permeable or impermeable. Solutions of calcium, fluoride and phosphate salts are particularly useful in the compositions of the invention. The microcapsules are preferably prepared by surfactant free inverse emulsion interfacial polymerization. Bone products include cements, scaffolds and bioactive glass. Dental products include pastes, gels, rinses and many other dental materials.

Anhydrous, solid antiperspirant compositions comprising: (a) from about 0.1% to about 30% by weight of the composition, of a high-efficacy antiperspirant active; (b) from about 0.1% to about 35% by weight of the composition, of a thickening agent; (c) from about 10% to about 99% by weight of the composition, of an anhydrous liquid carrier; (d) from about 5 ppm to about 20% by weight of the composition, of a primary fragrance; and (e) from at least about 5 ppm by weight of the composition, of a secondary fragrance that is distinct from the primary fragrance and is included in a surfactant-free, water-releasable matrix, which renders the secondary fragrance within the matrix substantially odorless prior to aqueous activation, wherein the anhydrous, solid antiperspirant composition exhibits an Antiperspirant Efficacy Index of at least about 0.9, and wherein the anhydrous, solid antiperspirant composition is substantially devoid of a malodor reducing agent.

The present invention provides a process in which no surfactant is used, or even if the surfactant is used the amount thereof is as small as possible, thus stably obtaining a suspension to carry out a crosslinking reaction. A production process for a crosslinked polymer particle, comprising the steps of: forming a suspension in which liquid drops of a first phase are dispersed in a second phase by stirring both phases in the presence of an inorganic particle, wherein the first phase includes a high-molecular compound and a crosslinking agent, and wherein the first phase and the second phase are insoluble in each other, and wherein the affinity of the inorganic particle for water is different from that of the high-molecular compound; and carrying out a crosslinking reaction. Furthermore, an approximately spherical crosslinked polymer particle, which is free from a surfactant.

A chemically prepared toner for electrophotographic printers and method therefor using a unique polymeric dispersant. The chemically prepared toner includes agglomerated polymeric dispersant stabilized pigment particles, a fuser release agent, a charge control agent dispersion, and a self-stabilized essentially surfactant free latex binder. The polymeric dispersant includes at least three segments, a hydrophilic polymeric segment, a hydrophobic polymeric segment, and a protective colloid or reactive surfactant segment. The weight average molecular weight range of the dispersant ranges from about 5,000 to about 30,000, and a hydrophobicity ranging from about 10 to about 90 percent by weight. The chemically prepared toner includes agglomerated toner particles have a unimodal particles size distribution with a number average particle size (N) ranging from about 5.0 to about 8.5 microns and a volume average particle size (V) ranging from about 5.0 to about 8.5 microns.

A surfactant free process for the preparation of toner comprising heating a mixture of an emulsion latex, a colorant, and a polyelectrolyte.

New compositions for use as protective coatings and / or adhesives are provided. The compositions comprise a hydrocarbon resin (e.g., terpene rosin) and a rubber (e.g., EPDM) dispersed or dissolved in a solvent system. The solvent system is preferably a single-solvent system, and the compositions are preferably free of surfactants, dyes, and chromophores. The compositions can be cured or dried to form layers or films that are chemically and thermally resistant, but that can be readily dissolved and removed at the appropriate stage in the fabrication process.

Antiperspirant compositions comprising: (a) from about 0.1% to about 30% by weight of the composition, of a high-efficacy antiperspirant active; (b) from about 0.05% to about 15% by weight of the composition, of a malodor reducing agent; (c) from about 0.1% to about 35% by weight of the composition, of a thickening agent; (d) from about 10% to about 99% by weight of the composition, of an anhydrous liquid carrier; (e) from about 0% to about 20% by weight of the composition, of a primary fragrance; and (f) from at least about 5 ppm by weight of the composition, of a secondary fragrance that is distinct from the primary fragrance and is included in a surfactant-free, water-releasable matrix, which renders the secondary fragrance within the matrix initially substantially odorless.

A cosmetic composition comprising (A) a first structured and adhesive film-forming fatty phase comprising (i) one or more lipidic components that are mutually compatible with one another when liquefied; (ii) at least one adhesive film-forming agent; and (iii) at least one lipophilic structuring agent in an amount effective to retain a second fatty phase entrapped in said cosmetic composition prior to application on mammalian keratinous tissue; and (B) a second fatty phase comprising at least one non-volatile lipidic component wherein said second fatty phase (B) is incompatible with said first structured and adhesive film-forming fatty phase (A) and said second fatty phase (B) is entrapped in said composition where upon application of said composition to mammalian keratinous tissue, said second fatty phase (B) readily separates from said composition to form a barrier layer over said first structured and adhesive film-forming fatty phase (A) and wherein said composition is substantially free of surfactants such that separation of said second fatty phase (B) from said composition is not prevented following application of said composition.

A process for preparing spherical alumina by oil-ammonia column includes dripping the alumina sol in the oil-ammonia column composed of upper oil phase and lower electrolyte solution phase to generate spherical gel particles, ageing in electrolyte solution for 0.5-10 hr, drying and calcining. Its advantage is high purity.

The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to an IL-9 polypeptide, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to an IL-9 polypeptide, which formulations are substantially free of surfactants, sugars, sugar alcohols, amino acids other than histidine (preferably with pKa values of less than 5 and above 7), and / or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating a disease or disorder associated with or characterized by aberrant expression and / or activity of an IL-9 polypeptide, a disease or disorder associated with or characterized by aberrant expression and / or activity of the IL-9R or one or more subunits thereof, an autoimmune disease, an inflammatory disease, a proliferative disease, or an infection (preferably, a respiratory infection), or one or more symptoms thereof, utilizing the liquid formulations of the present invention.

The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin alphaVbeta3, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin alphaVbeta3, which formulations are substantially free of surfactant, inorganic salts, and / or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and / or activity of integrin alphaVbeta3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.

The invention provides an apparatus for comminuting coal or other fuel solids in a shear field, and for optionally coating the solids with catalysts for combustion, liquefaction, and or gasification during the milling process. The apparatus further provides for control of water content in the solids may be controlled before, during and after the milling in order to obtain micronized solids with fine hydration layers. The output fuel solids of the apparatus can burn at low temperatures, avoiding emissions of nitrogen oxides, and they also have improved properties for surfactant-free suspension in either water or oil media, as well as for liquefaction and gasification.

Antiperspirant compositions comprising: (a) from about 0.1% to about 30% by weight of the composition, of a high-efficacy antiperspirant active; (b) from about 0.1% to about 35% by weight of the composition, of a thickening agent; (c) from about 10% to about 99% by weight of the composition, of an anhydrous liquid carrier; (d) from about 5 ppm to about 20% by weight of the composition, of a primary fragrance; and (e) from at least about 5 ppm by weight of the composition, of a secondary fragrance that is distinct from the primary fragrance and is included in a surfactant-free, water-releasable matrix, which renders the secondary fragrance within the matrix substantially odorless prior to aqueous activation, wherein the antiperspirant composition is substantially devoid of a malodor reducing agent.

The present application relates to a composition in the form of an oil-in-water emulsion comprising an oily phase dispersed in an aqueous phase, characterized in that the composition is free of surfactant and in that it contains cellulose fibrils which have a length of greater than 1 micron and a length / diameter ratio of greater than 30. The invention also relates to the use of the composition, especially for the care, the treatment, the makeup or the cleansing of the skin, lips, eyelashes and / or hair, as well as for the care of sensitive or dry skin.

The invention discloses a gefitinib dispersible tablet, a preparation method and an application thereof. The gefitinib dispersible tablet of the invention comprises the following components by weight: 10-65% of gefitinib, 1-30% of fillers, 10-50% of disintegrants, 1-60% of acidifiers, 0.1-20% of adhesives, and 0.1-30% of lubricants and glidants. According to the invention, gefitinib is wrapped bythe acidifier or gefitinib and the acidifier are wrapped with each other so as to reach the embedding effect. Compared with commercially available common tablets, the gefitinib dispersible tablet of the invention does not contain surfactants, has good dissolvability, dispersibility and disintegrability, and can be disintegrated completely within one minute. The gefitinib dispersible tablet prepared by the method of the invention has a high dissolution rate, good bioavailability, rapid distribution in vivo, and stable quality, and the preparation method is simple and practical, and is applicable to industrial production.

Anhydrous, solid antiperspirant compositions comprising: (a) from about 0.1% to about 30% by weight of the composition, of a high-efficacy antiperspirant active; (b) from about 0.05% to about 15% by weight of the composition, of a malodor reducing agent; (c) from about 0.1% to about 35% by weight of the composition, of a thickening agent; (d) from about 10% to about 99% by weight of the composition, of an anhydrous liquid carrier; (e) from about 0% to about 20% by weight of the composition, of a primary fragrance; and (f) from at least about 5 ppm by weight of the composition, of a secondary fragrance that is distinct from the primary fragrance and is included in a surfactant-free, water-releasable matrix, which renders the secondary fragrance within the matrix initially substantially odorless wherein the anhydrous, solid antiperspirant composition exhibits an Antiperspirant Efficacy Index of at least about 0.9.

In one embodiment, the present invention provides a drilling fluid composition that comprises a surfactant-free emulsion comprising an oleaginous fluid, a fluid that is at least partially immiscible with the oleaginous fluid, and a non-surfactant polymeric emulsifier. In another embodiment, the present invention provides a method of treating a subterranean formation comprising providing a treatment fluid that comprises a surfactant-free emulsion, the surfactant-free emulsion comprising an oleaginous fluid, a fluid that is at least partially immiscible with the oleaginous fluid, and a non-surfactant polymeric emulsifier; and treating the subterranean formation.

The present invention relates to a sunscreen formulation which exhibits superior ultraviolet protection and water resistance than prior art sunscreen compositions. The sunscreen formulation comprises (a) a dispersion comprising a sunscreen active agent and (b) a base composition comprising a rheological modifying agent and water. The sunscreen formulation is substantially free of surfactants. According to a preferred embodiment, the sunscreen active agent is ethylhexylmethoxycinnamate, butylmethoxydibenzoylmethane, or a combination thereof. The sunscreen formulation preferably comprises a phosphorylated starch derivative as a rheological modifying agent. Another embodiment of the present invention is a method of protecting skin or hair from ultraviolet radiation by applying an effective amount of the sunscreen formulation of the present invention to the skin or hair.

Anhydrous, solid antiperspirant compositions comprising: (a) from about 0.1% to about 30% by weight of the composition, of a high-efficacy antiperspirant active; (b) from about 0.05% to about 15% by weight of the composition, of a malodor reducing agent; (c) from about 0.1% to about 35% by weight of the composition, of a thickening agent; (d) from about 10% to about 99% by weight of the composition, of an anhydrous liquid carrier; (e) from about 5 ppm to about 20% by weight of the composition, of a primary fragrance; and (f) from at least about 5 ppm by weight of the composition, of a secondary fragrance that is distinct from the primary fragrance and is included in a surfactant-free, water-releasable matrix, which renders the secondary fragrance within the matrix substantially odorless prior to aqueous activation and wherein the anhydrous, solid antiperspirant composition exhibits an Antiperspirant Efficacy Index of at least about 0.9.

The present invention is directed to a long wear, waterproof eye makeup composition having a creamy texture and feel containing: (a) at least one polyamine; (b) an oil-soluble polar modified polymer; (c) water; (d) at least one non-volatile oil capable of solubilizing the oil-soluble polar modified polymer; (d) at least one volatile solvent; (e) at least one wax, and (f) optionally, at least one colorant, wherein the composition does not require a surfactant / emulsifier or can be surfactant- or emulsifier-free.

The invention provides core-shell hybrid latexes wherein the core comprises poly(acrylate)polymers and the shell comprises vegetable oil-based waterborne polyurethanes, and the latexes lack surfactants. Surfactant-free core-shell hybrid latexes with waterborne vegetable oil-based polyurethanes as the shell and poly(acrylate) as the core have been successfully prepared by seeded emulsion polymerization. The crosslink densities of the polymers obtained can be controlled by using modified vegetable oil polyols with various hydroxyl numbers or by adding a multifunctional vinyl crosslinker to the poly(acrylate) core.

The invention relates to a preparation method of polysilsesquioxane hollow microspheres. In the method, a trifunctional silane monomer is used as a raw material, an organic solvent is used as a template and the polysilsesquioxane hollow microspheres are prepared by utilizing the oil-in-water (O / W) suspension polymerization. According to the invention, the raw material is easy to obtain, the reaction condition is mild, the method is simple and convenient to operate, the step of removing a template core does not need to be carried out, and the cost is low. The hollow microspheres prepared by the method disclosed by the invention are white powder particles, have a polysilsesquioxane organic-inorganic hybrid material as a component, have low density and good mechanical strength, do not contain a surfactant, have physiological inert and can be loaded with object molecules. The particle sizes of the polysilsesquioxane hollow microspheres can be controlled in the range of 200nm to 5.0mum. The polysilsesquioxane hollow microspheres can be used as high-end packing, light scattering particles, a medicament and catalyst carrier, a microreactor and the like and are widely used for the fields of chemical industry, cosmetics, catalysis, separation, medicinal preparation, environmental protection and the like.

The invention relates to 17-HPC pulmonary formulations for administration by inhalation comprising 17-HPC and a pharmaceutically acceptable excipient. Particle size reduction of 17-HPC is required for the pulmonary delivery, and can be achieved with a surfactant or water without the surfactant. Preferred pulmonary formulations include a powder blend comprising a therapeutically effective amount of at least one steroid hormone (progestogen) as a glucocorticoid sensitizer, and at least one pharmaceutically acceptable excipient, wherein the at least one steroid hormone (progestogen) has a particle size distribution profile ranging from about one nanometer to about ten microns in the powder blend.

Cleansing and multifunctional coating compositions containing an organosilane quaternary compound, nonreactive abrasives, and hydrogen peroxide in aqueous formulations are used to improve water and soil repellency and residual antimicrobial activity on surfaces. Various surfaces may be treated including metal, glass, plastics, rubber, porcelain, ceramic, marble, granite, cement, tile, sand, silica, enameled appliances, polyurethane, polyester, polyacrylic, melamine / phenolic resins, polycarbonate, painted surfaces, wood, and the like.